| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ardelyx, Inc. (ARDX) has 9 insiders with recent SEC Form 4 filings, including 18 buys and 2 sells. ARDX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 3.30M | $20.84M | - | |
| CEO | 1.74M | $10.98M | -41,666 | |
| Other | 409.9K | $2.59M | - | |
| CFO | 409.1K | $2.58M | - | |
| Other | 339.5K | $2.14M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 18, 2016 | Nea 15 Gp, LLC | 10% Owner | Buy | 1,527,301 | $8.73 | $13,333,337.73 | +40.2% | |
| Mar 21, 2016 | Ringold Gordon | Director | Buy | 15,000 | $7.77 | $116,539.50 | New | |
| Mar 3, 2016 | Rosenbaum David P.59 | SVP, Drug Development | Sell | 1,128 | $10.74 | $12,109.87 | -4.8% | |
| Feb 16, 2016 | Kaufmann Mark | Chief Financial Officer | Sale+OE | 5,000 | $10.25 | $51,271.50 | -79.6% | |
| Jan 13, 2016 | Barris Peter J | 10% Owner | Buy | 1,500,000 | $10.00 | $15,000,000.00 | +14.6% | |
| Jan 13, 2016 | Kolluri Krishna Kittu | 10% Owner | Buy | 1,500,000 | $10.00 | $15,000,000.00 | +14.6% | |
| Jan 13, 2016 | Sandell Scott D55 | 10% Owner | Buy | 1,500,000 | $10.00 | $15,000,000.00 | +14.6% | |
| Jan 13, 2016 | Sakoda Jon | 10% Owner | Buy | 1,000,000 | $10.00 | $10,000,000.00 | +35.7% | |
| Jan 13, 2016 | Weller Harry R | 10% Owner | Buy | 1,000,000 | $10.00 | $10,000,000.00 | +35.7% | |
| Jan 13, 2016 | Viswanathan Ravi | 10% Owner | Buy | 1,000,000 | $10.00 | $10,000,000.00 | +35.7% |